Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
Intellect Neurosciences, Inc. (OTCBB: ILNS) announced today that it has filed an appeal regarding a preliminary decision of the European Patent Office to revoke the company's ANTISENILIN® patents. The preliminary decision of the EPO resulted from a challenge by major pharmaceutical companies that are co-developing Bapineuzumab, which is in Phase 3 clinical trials for Alzheimer's disease. Intellect has ANTISENILIN® patents pending in the United States and has been granted patents in Japan, China and several other countries. None of the patents granted outside Europe were challenged.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.